Skip to content
10-Q

Quarterly Report

Turning Point Therapeutics, Inc.

0000950170-22-008971

← back to feed
Filed
May 10, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2022 · May 3, 2022 49.67M sh
Capex Q1 2022 · Mar 31, 2022 $447K
Capex Q1 2022 · Mar 31, 2021 $143K
Operating Cash Flow Q1 2022 · Mar 31, 2022 −$58.33M
Operating Cash Flow restated Q1 2022 · Mar 31, 2021 −$15.65M
Cash And Equivalents Q1 2022 · Mar 31, 2022 $309.53M
Cash And Equivalents Q1 2022 · Dec 31, 2021 $427.88M
Cash And Equivalents Q1 2022 · Mar 31, 2021 $469.17M
Stockholders Equity Q1 2022 · Mar 31, 2022 $891.35M
Stockholders Equity Q1 2022 · Dec 31, 2021 $954.43M
Stockholders Equity Q1 2022 · Mar 31, 2021 $1.1B
Stockholders Equity Q1 2022 · Dec 31, 2020 $1.11B
Current Liabilities Q1 2022 · Mar 31, 2022 $45.57M
Current Liabilities Q1 2022 · Dec 31, 2021 $47.09M
Current Assets Q1 2022 · Mar 31, 2022 $927.43M
Current Assets Q1 2022 · Dec 31, 2021 $992.46M
Total Assets Q1 2022 · Mar 31, 2022 $938.79M
Total Assets Q1 2022 · Dec 31, 2021 $1B
Sga Expense Q1 2022 · Mar 31, 2022 $20.31M
Sga Expense Q1 2022 · Mar 31, 2021 $19.99M
Rd Expense Q1 2022 · Mar 31, 2022 $55.05M
Rd Expense Q1 2022 · Mar 31, 2021 $41.26M
Net Income Q1 2022 · Mar 31, 2022 −$74.45M
Net Income Q1 2022 · Mar 31, 2021 −$35.5M
Operating Income Q1 2022 · Mar 31, 2022 −$74.94M
Operating Income Q1 2022 · Mar 31, 2021 −$36.05M
Revenue Q1 2022 · Mar 31, 2022 $429K
Revenue Q1 2022 · Mar 31, 2021 $25.21M